Patanjali takes U-turn, says never claimed it can cure COVID-19
New Delhi : After a strong debate on Coronil as a treatment for coronavirus, Patanjali Ayurved Chief Executive Officer Acharya Balkrishna on Tuesday made a U-turn and noted that they never claimed medicines, Coronil and Swasari, as a cure of the infection. The Centre had barred the firm from advertising the products after Ramdev, in a sensational claim last week, said they cured 280 patients within days in trials.
"We never said the medicine (coronil) can cure or control corona, we said that we had made medicines and used them in clinical controlled trial which cured corona patients. There is no confusion in it," Acharya Balkrishna, CEO Patanjali, was quoted as saying by news agency ANI.
AYUSH Ministry had asked Patanjali to provide details over composition of the medicine and also the clinical research data which was claimed by the firm.
A licensing officer had later said the company sought a license for an "immunity booster and a cough and fever cure" and it never revealed that the products were part of medicine kits. The state government had sent a notice to the company.
"In reply to our notice, Patanjali said no Corona Kit has been packaged by them. Patanjali has printed a representative picture of coronavirus on Coronil packaging. Samples of Coronil and two other drugs have been taken for testing," YS Rawat, Licence Officer, Uttarakhand Ayurved Department, was quoted as saying by news agency ANI on Tuesday.
Yogaguru Ramdev had claimed that the firm had collaborated with NIMS for clinical trials.
"We are launching COVID medicines Coronil and Swasari today. We conducted two trials of these, first clinical controlled study, which took place in Delhi, Ahmedabad, among many other cities. Under this, 280 patients were included and 100 per cent of those recovered. We were able to control Corona and its complications in this. After this the all-important clinical control trial was conducted," he had said.
"With the help of NIMS, Jaipur we conducted the clinical control study on 95 patients. The biggest thing which came out of this is that within three days 69 per cent patients recovered and became negative from positive (cases) and within seven days 100 per cent of them became negative," he added.
